Catalent, Inc. (CTLT), a global company that provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products yesterday reported their fiscal fourth quarter 2017 financial results.

Catalent reported adjusted fourth quarter earnings of $0.65 per share which beat analyst expectations of $0.57 per share and revenues of $616.9 million which beat analyst expectations of $544.4 million.   

Catalent, Inc. CEO’s  Comments

“We’re pleased with our performance during the fourth quarter, where we recorded double-digit organic revenue growth and segment EBITDA growth on a constant-currency basis across all three of our reporting segments,” said John Chiminski, Chairman, President and Chief Executive Officer of Catalent, Inc. “Fiscal year 2017 was strong across many fronts with financial performance above our long-term outlook, significant levels of free cash flow generation, and the completion of two strategic acquisitions, Pharmatek and Accucaps, both of which are already creating value for the company and our shareholders.”  Business Wire

CTLT Technical Analysis

(Click on image to enlarge)

CTLT opened trading yesterday at $35.31 which was up from the previous day’s trading close of $35.20. CTLT closed trading yesterday at $35.36 and spiked up after market to $39.83, equivalent to a 13% increase from the closing price. Taking a look at the daily chart we can see that we are in unchartered territory as with the spike up CTLT is now trading at all time highs.

Taking a closer look at the daily chart we can see that before the spike up CTLT had already been in an overall upward trend dating back to May 4th when it traded at $28.93. CTLT has a float of 124.22 million shares and traded 1.73 times the normal daily trading volume on Monday.